financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
Mar 4, 2024 11:01 PM

01:00 PM EST, 02/29/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target to $71 from $47 on a P/S of 7.5x, above its three-year average on good sales execution and a favorable deal pipeline, using our next-12-month sales estimate of $2.3B. We lift our FY 24 EPS view to $1.07 from $0.95 and FY 25's to $1.33 from $1.21. NTNX posted Q2 sales of $565.2M, above consensus by $14.8M, while non-GAAP EPS of $0.46 beat by $0.17. Revenue rose 16.2% Y/Y from solid Subscription revenue growth (+18% Y/Y) as ACV billings outperformed, up 23% Y/Y, from higher-than-anticipated renewals. We note NTNX's commentary around a continued uncertain macro environment, and longer average sales cycles, which likely impacted contract duration of 2.8 years in Q2, lower than Q1. However, these results reflect the firm's strong execution in securing and keeping pace with renewals and expansion deals, as well as maintaining healthy pricing levels in spite of these challenges. Its upbeat guidance and a higher mix of large deals in the pipeline further support our positive view of the business.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Maintains Sell Opinion On Shares Of Crown Castle Inc.
Research Alert: CFRA Maintains Sell Opinion On Shares Of Crown Castle Inc.
Oct 22, 2025
01:40 AM EDT, 10/23/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target price at $86, applying an EV/EBITDA multiple of 24.3x to our 2026 estimate, a premium to its one-year historical average multiple at 21.8x given the...
Research Alert: CFRA Raises Opinion On Adss Of Barclays Plc To Buy From Hold
Research Alert: CFRA Raises Opinion On Adss Of Barclays Plc To Buy From Hold
Oct 22, 2025
01:20 AM EDT, 10/23/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price to USD24 (from USD21), reflecting 2026 P/E of 8.82x. This represents a premium to BARC's five-year historical forward P/E average of 7.46x, which we...
Research Alert: CFRA Lifts Opinion On Shares Of Ge Vernova Inc. From Hold To Buy
Research Alert: CFRA Lifts Opinion On Shares Of Ge Vernova Inc. From Hold To Buy
Oct 22, 2025
01:00 AM EDT, 10/23/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Following Q3 earnings, we lift our view on shares from Hold to Buy. Despite our valuation concerns previously, GEV is now trading at a more rational level, moderating from a...
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Boston Scientific Corporation
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Boston Scientific Corporation
Oct 23, 2025
04:25 AM EDT, 10/23/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We adjust our 12-month target price to $125 from $127, valuing shares at 36.8x our 2026 EPS outlook of $3.40 (up from $3.35; 2025 EPS lifted to $3.04 from $2.98),...
Copyright 2023-2026 - www.financetom.com All Rights Reserved